RT Journal Article
T1 Treatment outcome in dually HIV-1 and HIV-2 coinfected patients living in Spain.
A1 Requena, Silvia
A1 Caballero, Estrella
A1 Lozano, Ana Belen
A1 Rios-Villegas, Maria Jose
A1 Benito, Rafael
A1 Rojo, Silvia
A1 Cabezas, Teresa
A1 Macià, Maria Dolores
A1 Nieto, Maria Del Carmen
A1 Soriano, Vicente
A1 de Mendoza, Carmen
K1 Antiretrovirals
K1 HIV-1
K1 HIV-2
AB Whereas HIV-1 has spread globally, HIV-2 is mainly found in West Africa where dual HIV-1/HIV-2 coinfection is nowadays uncommon. Herein, we report the rate, main characteristics, and treatment outcomes of all dually infected patients living in Spain. We identified retrospectively all persons coinfected with HIV-1 recorded at the Spanish HIV-2 registry. Dual infection had been confirmed using PCR in plasma and/or cells, and/or using discriminatory serological tests. From a total of 373 individuals with HIV-2 recorded at the Spanish registry, 34 (9.1%) were coinfected with HIV-1. Compared with HIV-2 monoinfected persons, dually infected patients were more often male (67.6%), presented with lower median CD4 cell counts (204 cells/μl), and had developed more frequently AIDS events (26.5%). Although 61.7% came from West Africa, 6 (17.6%) were native Spaniards. HIV-1 non-B subtypes were recognized in 75% of coinfected patients, being the most prevalent CRF02_AG. At baseline, 45% of dually infected patients had undetectable plasma HIV-2 RNA. After a median follow-up of 32 (13-48) months on antiretroviral therapy, dually infected patients achieved undetectable viremia in 85% for HIV-1, in 80% for HIV-2; and in 70% for both viruses. Median CD4 cell counts reached up to 418 cells/μl. Roughly 9% of individuals with HIV-2 infection living in Spain are coinfected with HIV-1. Overall, 70% of dually infected patients achieved viral suppression for both viruses under antiretroviral therapy. Given the relatively large population of West Africans living in Spain and the continuous migration flow from HIV-2 endemic areas, HIV-1/HIV-2 coinfection should always be excluded at first diagnosis in all HIV-seroreactive persons.
PB Wolters Kluwer
YR 2019
FD 2019-07-12
LK http://hdl.handle.net/10668/14358
UL http://hdl.handle.net/10668/14358
LA en
NO Requena S, Caballero E, Lozano AB, Ríos-Villegas MJ, Benito R, Rojo S, et al. Treatment outcome in dually HIV-1 and HIV-2 coinfected patients living in Spain. AIDS. 2019 Nov 15;33(14):2167-2172
NO We would like to thank the participation of all members of the Spanish HIV-2 Network. This work was supported in part by grants from Fundacion Investigaci  on y Educacion en SIDA (F-IES); FIPSE (36742/08); Fondo de Investigacion Sanitaria-Fondos FEDER (FIS EC10/277, CES12/003, FI14/00264, CD14/00243), and the European Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN, project FP7–223131).
DS RISalud
RD Apr 11, 2025